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Dias, Ana Carolina Rodrigues, Melissa Vitela, Eduardo Colom-
bari, and Steven W. Mifflin. Nitric oxide modulation of glutamater-
gic, baroreflex, and cardiopulmonary transmission in the nucleus of
the solitary tract. Am J Physiol Heart Circ Physiol 288: H256–H262,
2005; doi:10.1152/ajpheart.01149.2003.—The neuromodulatory ef-
fect of NO on glutamatergic transmission has been studied in several
brain areas. Our previous single-cell studies suggested that NO facil-
itates glutamatergic transmission in the nucleus of the solitary tract
(NTS). In this study, we examined the effect of the nitric oxide
synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME)
on glutamatergic and reflex transmission in the NTS. We measured
mean arterial pressure (MAP), heart rate (HR), and renal sympathetic
nerve activity (RSNA) from Inactin-anesthetized Sprague-Dawley
rats. Bilateral microinjections of L-NAME (10 nmol/100 nl) into the
NTS did not cause significant changes in basal MAP, HR, or RSNA.
Unilateral microinjection of (RS)--amino-3-hydroxy-5-methylisox-
azole-4-propionic acid (AMPA, 1 pmol/100 nl) into the NTS de-
creased MAP and RSNA. Fifteen minutes after L-NAME microinjec-
tions, AMPA-evoked cardiovascular changes were significantly reduced.
N-methyl-D-aspartate (NMDA, 0.5 pmol/100 nl) microinjection into the
NTS decreased MAP, HR, and RSNA. NMDA-evoked falls in MAP,
HR, and RSNA were significantly reduced 30 min after L-NAME. To
examine baroreceptor and cardiopulmonary reflex function, L-NAME
was microinjected at multiple sites within the rostro-caudal extent of the
NTS. Baroreflex function was tested with phenylephrine (PE, 25 g iv)
before and after L-NAME. Five minutes after L-NAME the decrease in
RSNA caused by PE was significantly reduced. To examine cardiopul-
monary reflex function, phenylbiguanide (PBG, 8 g/kg) was injected
into the right atrium. PBG-evoked hypotension, bradycardia, and RSNA
reduction were significantly attenuated 5 min after L-NAME. Our results
indicate that inhibition of NOS within the NTS attenuates baro- and
cardiopulmonary reflexes, suggesting that NO plays a physiologically
significant neuromodulatory role in cardiovascular regulation.
(RS)--amino-3-hydroxy-5-methylisoxazole-4-propionic acid; N-
methyl-D-aspartate; baroreceptor and cardiopulmonary reflexes;
cardiovascular regulation; renal sympathetic nerve activity
ANATOMIC AND PHYSIOLOGICAL studies suggest interactions be-
tween NO and glutamatergic transmission within the nucleus
of the solitary tract (NTS) that could modulate cardiovascular
regulation (11, 12, 14, 15, 19, 28). L-Glutamate and the
synthetic enzyme for production of NO, nitric oxide synthase
(NOS), have been colocalized in nerve terminals and neurons
within the NTS (8, 13–15, 25, 28). NOS immunoreactivity is
also found in other neurons in the medulla oblongata that
project to the NTS (3, 25). Activation of glutamatergic recep-
tors in the NTS elicits the production and release of NO and
other nitrosyl substances with neurotransmitter/neuromodula-
tor properties (2, 19). Therefore, all of the substrates necessary
for NO production are present in the NTS.
Microdialysis or microinjection of NOS inhibitors into the
NTS reduces extracellular levels of glutamate (11) and the
cardiovascular responses evoked by NTS microinjections of
ionotropic excitatory amino acid agonists (12, 19). Iontophore-
sis of an inhibitor of NOS, NG-nitro-L-arginine methyl ester
(L-NAME), does not alter spontaneous discharge but signifi-
cantly decreases the number of action potentials evoked by
iontophoretic application of (RS)--amino-3-hydroxy-5-meth-
ylisoxazole-4-propionic acid (AMPA) in NTS neurons receiv-
ing vagal afferent inputs (1). In addition, iontophoresis of a NO
donor enhances spontaneous discharge and the number of
action potentials elicited by AMPA, suggesting that NO could
be facilitating AMPA-mediated neuronal transmission within
the NTS (1).
If NO facilitates glutamatergic transmission within the NTS,
inhibition of NO production should reduce cardiovascular
responses elicited by stimulation of glutamatergic receptors
and stimulation of cardiovascular afferent inputs known to
utilize glutamatergic transmission (baroreceptor, cardiopulmo-
nary). The specific aim of this study was to examine the
participation of NO in the cardiovascular responses elicited by
stimulation of N-methyl-D-aspartate (NMDA) and AMPA re-
ceptors in the NTS, as well as the functional significance of
these interactions in the cardiovascular responses evoked by
activation of peripheral baroreceptors and cardiopulmonary
receptors.
MATERIALS AND METHODS
Animals. Experiments were performed on male Sprague-Dawley
rats (300–400 g; Charles River). Rats were housed in a laboratory
animal room, two per cage, with unrestricted access to food and water.
All animals were given at least 1 wk to acclimatize before use. All
experimental protocols were approved by the Institutional Animal
Care and Use Committee and were in accordance with US Public
Health Service guidelines.
Preparation. Animals were anesthetized with Inactin (100 mg/kg
ip; Sigma) and placed on a thermostatically controlled heating pad.
The trachea was cannulated, and the rat was artificially ventilated with
room air supplemented with 100% O2. Catheters were placed in the
femoral artery and vein for blood pressure monitoring and injection of
drugs. Arterial pressure was measured with a Cobe CDX transducer
(Cobe Laboratories, Lakewood, CO). Mean arterial pressure (MAP,
mmHg) and heart rate (HR, beats/min) were determined from the
pulsatile signal with a Coulbourn blood pressure processor. Gallamine
thiethiodide (20 mg/kg initially, supplemented with 5 mg as needed,
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typically every hour) was also given for paralysis. Depth of anesthesia
was gauged by the stability of blood pressure and HR and the absence
of a pressor response to paw pinch. The rat was placed in a stereotaxic
frame, and an occipital craniotomy was performed to expose the
dorsal surface of the medulla in the region of obex. Cardiopulmonary
receptors were stimulated by right atrial injections of phenylbiguanide
(PBG) via a PE-50 tube in the jugular vein.
Renal sympathetic nerve activity. The postganglionic renal nerve
bundle was isolated through a flank retroperitoneal incision and
mounted, intact, on a bipolar Teflon-coated stainless steel wire elec-
trode (0.0071-in. bare diameter; Cooner Wire, Austin, TX). When the
optimal signal was obtained, the nerve was fixed in place with a
silicone impression material (polyvinylsiloxane; Super-Dent) and the
flank wound was closed. The nerve signal was fed through an
alternating current amplifier (P5; Grass Instruments, Quincy, MA) via
a high-impedance probe, amplified 20,000–100,000 times, and fil-
tered between 300 and 3,000 Hz. The 0% and 100% reference levels
of nerve activity were obtained by recording the noise level after
inhibition and stimulation of nerve activity with a 0.15-ml bolus
injection of phenylephrine (PE, 100 g/ml) and sodium nitroprusside
(250 g/ml), respectively. The resting level of renal sympathetic
nerve activity (RSNA) was placed within the 0–100% scale, and
reductions in RSNA are presented as a percent decrease relative to the
resting level of RSNA.
NTS microinjections. Rats were placed in a stereotaxic frame with
the head inclined 45° downward for better visualization of the cala-
mus scriptorius. Drugs were injected through glass pipettes by pres-
surized N2 pulses with a pressure ejection system. The volume of the
injection (100 nl) was determined by viewing the movement of the
fluid meniscus inside the pipette by a microscope with a calibrated
micrometer. Unilateral AMPA and NMDA microinjections and bilat-
eral L-NAME and NG-nitro-D-arginine methyl ester (D-NAME) mi-
croinjections were made into the NTS with the following coordinates:
0.5 mm rostral to calamus, 0.5 mm lateral to midline, and 0.5 mm
ventral from the surface of the medulla. In the cardiopulmonary and
baroreceptor reflex protocols, L-NAME or D-NAME microinjections
were made at two sites on each side of the NTS and one site caudal
to the calamus scriptorius (volume of microinjection was 60 nl/site),
as shown in Fig. 1. After the experiment, a micropipette containing
Chicago sky blue 2% was positioned at the sites of microinjections for
postmortem analysis of injection sites.
Histology. Animals were transcardially perfused with saline (0.9%)
followed by 10% formalin solution. The brain was removed, and
40-m sections were cut with a microtome. Sites of microinjection
were identified under the microscope after staining by the Nissl
method (neutral red). Data obtained from microinjection sites located
in the NTS at the level of the calamus scriptorius were used for
analysis.
Data analysis. Pulsatile arterial pressure, MAP, HR, and RSNA
were recorded with a PC-based data acquisition system (Spike 2;
Cambridge Electronic Design, London, UK). RSNA was monitored
on a digital oscilloscope (Nicolet Instrument, Madison, WI) and an
audio monitor (Grass Instruments). MAP and HR were determined
from the arterial pressure pulse (Coulbourn Instruments). Differences
in RSNA between treatment and baseline were measured over the
same interval period (10–15 s). All data are presented as means SE.
Results were analyzed by one-way ANOVA with repeated measures
followed by Newman-Keuls post hoc test. Significance was accepted
for P  0.05.
RESULTS
Effects of NOS inhibition on responses to NTS microinjec-
tions of AMPA. One group of animals (n  8; basal MAP
104  3 mmHg, basal HR 344  10 beats/min) was unilater-
ally microinjected with 1 pmol/100 nl of AMPA into the NTS
before and 5, 15, 30, and 45 min after the bilateral microin-
jection of L-NAME (10 nmol). Bilateral microinjection of
L-NAME did not change MAP, HR, or RSNA (MAP: basal
104  4, after L-NAME 107  10 mmHg; HR: basal 339  8,
after L-NAME 338 5 beats/min; RSNA: basal 45 8%, after
L-NAME 32  16%; n  8). Before L-NAME injections,
AMPA microinjection elicited significant reductions in MAP
Fig. 1. Schematic representation of the dor-
sal surface of the medulla indicating the sites
(1–5) of microinjection into the nucleus of
the solitary tract (NTS). Site 1 was caudal to
the calamus scriptorius. Sites 2 and 3 indi-
cate intermediate NTS and sites 4 and 5 the
rostral portion of NTS. Respective coordi-
nates are presented in the table (top). Bot-
tom: composite of injection sites (dark gray
shading) in coronal sections of brain stem at
rostral (A), intermediate (B), and caudal (C)
NTS from 24 rats.
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(MAP: 33  3 mmHg, P  0.002, n  8), RSNA
(RSNA: 66  10% from basal, P  0.001, n  8), and HR
(HR: 18  7 beats/min, P  0.05, n  5). AMPA-evoked
reductions in MAP and RSNA were attenuated 5 and 15 min
after NOS inhibition (MAP: 5 min 23  6, 15 min 22 
6 mmHg; RSNA: 5 min43 6%, 15 min46 9% from
basal; P 0.05, n 8; Fig. 2). No changes in the HR response
to AMPA microinjections were observed after L-NAME.
To test the specificity of L-NAME on the responses shown
above, the same protocol was performed in another group of
animals (n  7; basal MAP 103  4 mmHg, basal HR 361 
14 beats/min) with the inactive enantiomer of L-NAME (D-
NAME, 10 nmol). D-NAME microinjection did not alter basal
or AMPA- evoked changes in MAP, HR, or RSNA (Fig. 2).
Effects of NOS inhibition on responses to NTS microinjec-
tions of NMDA. Interactions between NMDA and L-NAME
within the NTS were examined in a separate group of animals
(n  8; basal MAP 101  3 mmHg, basal HR 342  9
beats/min). A representative example of changes in MAP, HR,
and RSNA caused by microinjection of NMDA before and
after L-NAME is shown in Fig. 3A.
Bilateral microinjection of L-NAME (10 nmol) did not
change MAP (basal 100  4, after L-NAME 95  6 mmHg)
and HR (basal 339  10, after L-NAME 321  11 beats/min).
RSNA was transiently, but significantly, reduced after
L-NAME microinjections (basal 32  13%, after L-NAME
22 12%, P 0.031; n 7) in this set of experiments. RSNA
returned to basal levels within a minute after the last microin-
jection of L-NAME. Before injections of L-NAME, NMDA
microinjections (0.5 pmol/100 nl) resulted in significant reduc-
tions in MAP, HR, and RSNA (MAP: 35  3 mmHg, n 
8; HR:23 4 beats/min, n 7; RSNA:44 7% from
basal, n  7; all P  0.001). Responses to NMDA microin-
jection were reduced 15 and 30 min after L-NAME (MAP: 15
min20 4, 30 min21 6 mmHg, P 0.05, n 8; HR:
15 min 7  3, 30 min 5  3 beats/min, P  0.05, n  7;
Fig. 4). The NMDA-evoked reduction in RSNA was attenuated
30 min after L-NAME (RSNA 30 min: 17  7% from
basal; P  0.05, n  7). This protocol was performed in
another group of rats (n 8; basal MAP 103 3 mmHg, basal
HR 337  11 beats/min), using the inactive enantiomer of
L-NAME (D-NAME, 10 nmol) to demonstrate the specificity of
L-NAME action in NTS. D-NAME microinjection did not alter
basal or NMDA-evoked changes in MAP, HR, and RSNA
(Fig. 4).
Effects of NTS NOS inhibition on responses to baroreceptor
stimulation. Intravenous injection of PE (0.1 ml, 25 g/kg)
increased MAP 20 mmHg and reduced RSNA 50%. In our
preparation, only slight reductions in HR were observed. PE
was injected before multiple NTS microinjections (see Fig. 1)
of L-NAME (control), 5–7 min after the last L-NAME injec-
tion, and 45 min after the last L-NAME injection (PE recov-
ery). A representative recording of changes in MAP, HR, and
RSNA caused by baroreceptor stimulation with PE before (PE
control) and after L-NAME is shown in Fig. 3B.
Microinjections of L-NAME over much of the rostro-caudal
extent of the NTS significantly decreased RSNA (from basal:
39  6% to 21  7% after L-NAME; P  0.024, n  7).
However, this reduction was transient and RSNA had returned
to basal levels before the following PE injection. NTS micro-
injections of L-NAME did not alter the increase in MAP
elicited by PE injection (MAP: PE control 23  2, PE after
L-NAME 25  2, PE recovery 24  2 mmHg; n  7). The
PE-evoked reduction in RSNA was significantly reduced 5–7
min after L-NAME (RSNA: PE control 47  7%, PE after
L-NAME24 7%, PE recovery47 5% from basal; P
0.02, n  7; Fig. 5A). The magnitude of the PE-evoked
bradycardia was low under control conditions and after L-
NAME (HR: PE control 5  1, PE after L-NAME 	1  3,
PE recovery 5  1 beats/min; n  7). Another group of
animals (n  7) had the same protocol performed with the
inactive enantiomer D-NAME instead of L-NAME, and no
Fig. 2. Change in mean arterial pressure
(MAP; top) and renal sympathetic nerve activ-
ity (RSNA; bottom) elicited by microinjection
of (RS)--amino-3-hydroxy-5-methylisoxazole-
4-propionic acid (AMPA, 1 pmol/100 nl) into the
NTS before (ampa c) and after [5, 15, 30 and 45
min (ampa 5, 15, 30, 45)] NG-nitro-L-arginine
methyl ester (L-NAME; left, n  8) and NG-
nitro-D-arginine methyl ester (D-NAME; right,
n  7) microinjections. *P  0.05, different
from control; †P 0.05, ampa 5 ampa 15 and
different from ampa 30.
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significant changes were observed in basal levels of MAP, HR,
or RSNA or in PE-evoked alterations in these variables.
Effects of NTS NOS inhibition on responses to cardiopul-
monary receptor stimulation. The site of action of the intra-
atrial PBG injection was localized to the cardiopulmonary
region by sequential denervations. In six rats intra-atrial injec-
tion of 0.1 ml PBG (8 g/kg) decreased MAP by 22  2
mmHg and HR by 27  4 beats/min. After bilateral subdia-
phragmatic vagotomy, PBG decreased MAP by 26  3 mmHg
and HR by 26 4 beats/min. After bilateral cervical vagotomy
PBG evoked an increase in MAP of 9  9 mmHg and a
decrease in HR of 4  10 beats/min.
Microinjections of L-NAME over much of the rostro-caudal
extent of the NTS elicited a significant decrease in RSNA
(from basal: 49  6% to 27  6% after L-NAME; P  0.004,
n  5). However, this reduction was transient and RSNA
returned to basal levels before the following PBG injection.
Intra-atrial injection of PBG evoked hypotension, bradycardia,
and a reduction in RSNA. PBG-evoked responses were signif-
icantly reduced 5–7 min after L-NAME (MAP: PBG control
36 5, PBG after L-NAME19 5, PBG recovery34
4 mmHg, P 0.001, n 5; HR: PBG control24 7, PBG
after L-NAME 5  2, PBG recovery, 17  7 beats/min,
P  0.020, n  5; RSNA: PBG control 35  5%, PBG
after L-NAME 15  2%, PBG recovery 28  4%, P 
0.017, n  5; Fig. 5B). Another group of animals (n  6) had
the same protocol performed with the inactive enantiomer
D-NAME instead of L-NAME, and no significant changes were
observed in basal levels or PBG-evoked changes in MAP, HR,
and RSNA.
DISCUSSION
Our previous single-cell study (1) demonstrated NO facili-
tation of excitatory amino acid-evoked excitation of NTS
neurons and suggested a functional role for NO within the NTS
in cardiovascular regulation. The present study supports the
idea that NO plays a functionally important role within the
NTS as a modulator of responses to excitatory amino acids as
well as responses to baroreceptor and cardiopulmonary recep-
tor activation.
In our preparation, inhibition of NOS within the NTS did not
alter basal MAP or HR, suggesting little, if any, tonic NO
release. Variable change or no change in basal levels of MAP
or HR after NTS microinjection of NO donors or NOS inhib-
itors has been reported by different labs. Inhibition of NOS (5,
18) or antisense-induced reduction in neuronal NOS (nNOS)
(17) were reported to increase MAP. Other studies reported
that inhibition of NOS (2, 22, 24) and specific inhibition of
nNOS (12, 22) do not change basal MAP or HR. Using gene
Fig. 3. Representative recordings of pulsatile arterial pressure (PAP), MAP, heart rate [HR, beats/min (bpm)], and RSNA after microinjection of N-methyl-D-
aspartate (NMDA) before (NMDA control) and after L-NAME into the NTS (A). B: responses to baroreceptor stimulation during phenylephrine (PE)-induced
increases in blood pressure before (PE control) and after L-NAME microinjections.
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transfer, Waki et al. (29) reduced expression of endothelial
NOS (eNOS) within the NTS and reported no change in basal
MAP but a reduction in HR. The variable results from these
studies could be due to the species used, the strain of rat used,
the presence or absence of anesthesia, as well as the precise
means used to increase or decrease NO. For example, the use
of L-NAME should inhibit both nNOS and eNOS. However, no
consistent pattern is apparent that would explain the results
from different labs.
We observed a transient decrease in the resting level of
RSNA after bilateral and multiple L-NAME microinjections in
the NTS. Within a minute after the last microinjection no
significant changes of MAP or HR were observed. It is not
likely that the transient reduction in RSNA was an artifact,
because it was not seen during NTS injections of the inactive
enantiomer D-NAME. The lack of sustained changes in RSNA
could reflect a specific effect of L-NAME within the NTS
region covered by the microinjection, or it could be a reflection
of small changes in multiple sympathetic outflows that are
insufficient to result in a change in MAP. The lack of sustained
change in basal MAP and RSNA after L-NAME injections
could also be due to remaining baroreflex buffering, because
injections of L-NAME at multiple sites within NTS only
reduced PE-evoked inhibition of RSNA by 50%. The lack of
Fig. 4. MAP (top) and RSNA (bottom)
elicited by microinjection of NMDA (0.5
pmol/100 nl) into the NTS before (nmda c)
and after [5, 15, 30, and 45 min (nmda 5, 15,
30, 45)] L-NAME (left, n 8) and D-NAME
(right, n  8) microinjections. *Different
from control, P  0.05.
Fig. 5. MAP and RSNA elicited by in-
fusion of PE (baroreflex, n  7; A) and
phenylbiguanide (PBG, cardiopulmonary,
n 5; B) before (control) and after L-NAME
microinjections into the NTS. *Different
from control, P  0.05.
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sustained change in MAP and RSNA after L-NAME injections
is consistent with our single-unit iontophoretic study (1), which
found no change in basal discharge frequency of NTS neurons
after iontophoretic application of L-NAME. Keeping in mind
the caveats discussed above, in our preparation NO within the
NTS does not appear to significantly contribute to tonic main-
tenance of MAP or RSNA.
Our results are consistent with previous studies that demon-
strated facilitatory interactions between excitatory amino acids
and NO within the NTS. Inhibition of NOS within the NTS
decreases cardiovascular responses evoked by microinjection
of glutamate and NMDA into the NTS (2, 19). Within the NTS,
selective inhibition of nNOS reduced cardiovascular responses
evoked by microinjection of AMPA (12) or NMDA (12, 28).
Within the NTS, increases in NO have been shown to induce
glutamate release (11) whereas microinjections of AMPA and
NMDA have been shown to increase NO levels (11, 19).
The present study confirms the physiological significance of
interactions between NO and glutamatergic transmission by
measuring the effects of NOS inhibition on cardiovascular
responses elicited by activation of NMDA and AMPA recep-
tors in the NTS. We also characterized the effects of NOS
inhibition on baroreceptor and cardiopulmonary receptor reflex
activation. Previous studies demonstrated that these afferents
utilize glutamatergic receptors within the NTS (4, 21, 26, 31)
and that NO may play a role in the reflex responses to
activation of these receptors (6, 10). NMDA- and AMPA-
elicited responses were significantly reduced after L-NAME
microinjection into the NTS. Cardiopulmonary receptor
evoked reductions in MAP, HR, and RSNA were attenuated by
NOS inhibition. Baroreceptor-evoked reductions in RSNA
were also attenuated. The small HR responses during barore-
ceptor stimulation are problematic and may be related to the
muscle paralytic agent used (gallamine), which has muscarinic
antagonist effects. However, cardiopulmonary receptor activa-
tion evoked reasonable reductions in HR, so it may be a
question of the relative intensity of the stimuli.
Several studies have examined the effects of NO within the
NTS on baroreflex and cardiopulmonary reflex function. Lewis
et al. (10) demonstrated that the processing of cardiopulmonary
afferent inputs within the NTS involves activation of soluble
guanylate cyclase. Paton’s group (22, 29) showed that endo-
thelial NOS attenuates baroreflex control of HR whereas
L-NAME inhibition of NOS or selective neuronal NOS inhi-
bition had no effect on baroreflex control of HR (22). It should
be noted that Waki et al. (29) used spontaneous changes in
systolic pressure and pulse interval as indexes of baroreflex
gain, and the specificity of these measures has been recently
questioned (16). Other groups have reported that alterations in
the NTS NO system have no significant effect on baroreflex
function (5, 7, 30), and others have shown that inhibition of
NOS (24), and more specifically nNOS, attenuates baroreflex
regulation of HR (20, 27) but not RSNA (20). The reason(s) for
the differences between studies is not obvious; however, spe-
cies, anesthetic, drug(s) used to interfere with NO, as well as
microinjection parameters (single vs. multiple injections),
stimulus used to evoke baroreflex responses, as well as output
being measured (HR vs. sympathetic nerve discharge) are all
variables that could contribute to the differences between
studies.
In addition, the relative intensity of the stimulus used to
evoke reflex responses might also contribute to differences
between studies of NO and baroreflex function. For example,
we found no change in the meager (5 beats/min) baroreflex-
evoked bradycardia following NTS injections of L-NAME,
whereas PBG-evoked bradycardia (27 beats/min) was signifi-
cantly attenuated. “Single-point” stimuli do not permit con-
struction of reflex curves; therefore, the present study could not
determine whether NO facilitates reflex function over the entire
operating range or over a restricted portion. A previous single-
unit recording study suggested that NO facilitation of excita-
tory amino acid-evoked discharge was most marked at high
levels of discharge frequency (1); therefore, in our preparation
NO may only facilitate reflex function in response to large
stimuli and/or high neuronal discharge frequency. We cannot
exclude possible interactions within the NTS between the NO
system and other neurotransmitters and/or inhibitory amino
acids known to modulate baroreceptor and cardiopulmonary
receptor reflexes (9, 23).
Our previous finding (1) that NO enhances excitatory amino
acid-evoked discharge in NTS neurons receiving vagal afferent
inputs provides a basis for the attenuation of baroreflex and
cardiopulmonary reflex inhibition of renal nerve discharge
after inhibition of NOS within the NTS reported in the present
study. We propose that L-NAME reduces NO facilitation of
excitatory amino acid-evoked discharge during activation of
baroreceptor or cardiopulmonary afferent fibers. This reduces
the activation of NTS neurons receiving these peripheral af-
ferent inputs and leads to reduced reflex responses.
The source of the NO mediating the observed effects could
be within vagal afferent terminals (13, 25) and/or within NTS
neurons (8, 14) possessing AMPA and/or NMDA receptors
(15). NO released by the postsynaptic neuron could act on the
same and/or adjacent cells, including the presynaptic neuron,
where it could modulate the release or production of other
neurotransmitters. The present data reinforce the idea that
interactions between glutamatergic receptors and NO within
the NTS can be functionally important in the modulation of
cardiovascular reflexes and raise the question of the potential
role of these interactions in pathophysiological states such as
hypertension.
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